

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AZURITY PHARMACEUTICALS, INC.
AZURITY PHARMA INDIA LLP
SLAYBACK PHARMA LLC,
Petitioners

v.

HERON THERAPEUTICS, INC.,
Patent Owner.

Case PGR2025-00035
Patent No. 12,115,254

PATENT OWNER'S CURRENT LIST OF EXHIBITS

LIST OF EXHIBITS

Exhibit No.	Description	Previously Submitted
2001	<i>Heron Therapeutics, Inc. v. Slayback Pharma LLC</i> (DNJ-2-24-cv-00423), D.I. 63 (“Defendants’ Reply Brief in Support of Motion to Transfer Venue to District of Delaware Pursuant to 28 U.S.C. § 1404(a) (Redacted)”)	X
2002	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), D.I. 81 (“Stipulation and Order to Amend Schedule”)	X
2003	Prosecution History for U.S. Application Serial No. 18/418,030 which issued as the ’255 patent (“’255 Patent Prosecution History”)	X
2004	<i>Heron Therapeutics, Inc. v. Slayback Pharma LLC</i> (DNJ-2-24-cv-00423), D.I. 1 (“Complaint for Patent Infringement”)	X
2005	<i>Heron Therapeutics, Inc. v. Slayback Pharma LLC</i> (DNJ-2-24-cv-00423), D.I. 59 (“Opinion Granting Motion to Transfer Venue to District of Delaware”)	X
2006	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), D.I. 1 (“Complaint for Patent Infringement”)	X
2007	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), D.I. 30 (“Scheduling Order”)	X
2008	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), 12/30/2025 Hearing Transcript (Redacted)	X
2009	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), 01/13/2025 Defendants’ Invalidity Contentions	X
2010	U.S. Patent 11,744,800 (“the ’800 patent”)	X
2011	U.S. Patent 12,290,520 (“the ’520 patent”)	X

2012	<i>Heron Therapeutics, Inc. v. Slayback Pharma LLC</i> (DDE-1-24-cv-00830), D.I. 80 (“Scheduling Order”)	X
2013	<i>Heron Therapeutics, Inc. v. Azurity Pharmaceuticals, Inc.</i> (DDE-1-24-cv-01363), D.I. 46 (“Joint Stipulation and Order Regarding Claim Construction”)	X
2014	04/28/2025 Email from J. Goldstein Regarding Reduction of Asserted Claims	X
2015	Prosecution History for U.S. Application Serial No. 18/408,486 which issued as the '254 patent (“’254 Patent Prosecution History”)	X
2016	<i>Heron Therapeutics, Inc. v. Fresenius Kabi USA, LLC</i> (DDE-1-22-cv-00985), D.I. 182 (“Fresenius’s Opening Post-Trial Brief (Redacted)”)	X
2017	Zhou Wei <i>et al.</i> , “Preparation of Aprepitant Emulsion for Intravenous Injection,” Chinese Journal of Pharmaceuticals, 2012, 43(12), 1003-1006 (“Zhou Article”)	
2018	Gonglun Chen & Daniel Tao, “An Experimental Study of Stability of Oil-In-Water Emulsion,” Fuel. Proc. Technol. 2005, 86, 499-508	

Respectfully submitted,

Dated: July 14, 2025

By: /Naveen Modi/
Naveen Modi (Reg. No. 46,224)
Counsel for Patent Owner
Counsel for Patent Owner

CERTIFICATE OF SERVICE

I certify that I caused to be served on the counsel identified below a true and correct copy of the foregoing Patent Owner's Current List of Exhibits by electronic means on July 14, 2025:

AzurityIPRs@windellsmarx.com
Andrew E. Morrell (amorrell@windellsmarx.com)
Robert A. Delafield II (rdelafield@windellsmarx.com)
Leah Digby (lkuhn@windellsmarx.com)

By: /Naveen Modi/
Naveen Modi (Reg. No. 46,224)